Executive Summary
Across the 26 Dow Jones 30 filings for 2026-11-03, insider activity dominates the flow: 15 of the 26 filings are Form 4 transactions, and the pattern is heavily skewed toward sales by executives at American Express, Visa, Procter & Gamble and Walmart, with several large exercise-and-sell events (e.g., Visa's CFO-equivalent Taneja, P&G's Raman at ~$6.3M, Amex's Seeger at ~$22.9M) pointing to routine liquidity rather than a coordinated bearish signal, since many carry 10b5-1 plan disclosures.
Director open-market purchases at Boeing (Buckley ~$998K, Mollenkopf ~$510K) and Caterpillar (Fish ~$620K) are the clearest insider-conviction signals in the group. Fundamentals are mixed: JPMorgan grew Q3 net income 6% and diluted EPS 10% but expenses rose 12% with the CET1 ratio down to 14.0% from 14.8%; Apple delivered FY2026 net sales up 15% to $478.8B and net income up 18%, but the effective tax rate rose to 17.0%; UnitedHealth's Q3 revenue slipped 0.4% YoY while earnings from operations rose 52.1%, and nine-month operating cash flow jumped 34.9%. Amgen showed revenue up 8% to $10.4B with strong growth in Repatha, EVENITY, UPLIZNA and IMDELLTRA, offset by Prolia (-45%) and XGEVA (-47%) erosion from biosimilars, while free cash flow fell to $3.7B from $4.2B and no buybacks were executed. Several issuers (P&G euro bond, Amazon 13F, Merck phantom stock) generated low-materiality filings with no performance data.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Form 4 · 8-K · 10-Q · 13F · 10-K
Tracking the trend? Catch up on the prior Dow Jones 30 Stocks SEC Filings digest from November 02, 2026.
Investment Signals (11)
- Boeing ↓ (BULLISH)▲
Two independent directors bought in the same window - Mollenkopf 2,950 shares at $173.03 (~$510K) and Buckley 5,820 shares at $171.55 (~$998K), a combined ~$1.5M open-market commitment
- Apple ↓ (BULLISH)▲
FY2026 net sales up 15% to $478,834M and net income up 18% to $132,175M; Services grew 13% to $123,301M and Greater China rebounded +28% after a prior-year 4% decline, with diluted EPS up 20% to $8.98
- Caterpillar ↓ (BULLISH)▲
Director James Fish bought 1,000 shares at $620.39 (~$620K), raising his holding to 4,714 shares - a modest but clean open-market purchase at a time when peers show insider selling
- Amgen ↓ (BULLISH)▲
Q3 revenue up 8% to $10.4B and GAAP EPS up 19% to $7.08, with Repatha +37%, EVENITY +39%, UPLIZNA +191% and IMDELLTRA +128% carrying the growth; non-GAAP EPS up 14% to $6.45
- UnitedHealth Group ↓ (BULLISH)▲
Earnings from operations rose 52.1% to $6,563M and diluted EPS rose to $4.56 from $2.59 despite Q3 revenue down 0.4%, while nine-month operating cash flow rose 34.9% to $25,087M
- JPMorgan Chase ↓ (BEARISH)▲
Q3 net income $15,305M (+6% YoY), diluted EPS $5.57 (+10%), nine-month net income up 20% to $52,954M, but noninterest expense +12% and overhead ratio up to 54% temper the quality of growth
- American Express ↓ (BEARISH)▲
Chief Legal Officer Seeger sold 69,860 shares at $328.17 (~$22.9M) after exercising at $148.45, retaining 9,002 shares; Group President Marrs sold ~31,463 shares (~$10.3M) in the same period, a cluster of senior-officer selling
- Visa ↓ (BEARISH)▲
President Technology Taneja sold 34,418 shares at $425.43 (~$14.6M) and CEO McInerney sold 5,875 shares (~$2.45M, 10b5-1); Taneja retains 232,112 shares, so the sale is material but not a full exit
- Procter & Gamble ↓ (BEARISH)▲
Four insiders sold in the window - CEO Raman (38,253 shares, ~$6.31M, 9/10 materiality), Aguilar (18,812 shares, ~$3.09M), Janzaruk (9,479 shares, ~$1.55M) and Gama (2,894 shares, ~$478K), all after option exercises at much lower strike prices
- Walmart ↓ (BEARISH)▲
CTO Kumar sold 166,342 shares at $123.21 (~$20.5M) under a 10b5-1 plan, retaining 1.63M shares; EVP Bartlett sold 3,346 shares (~$417K), both disclosed as pre-planned
- Disney (BEARISH)▲
EVP Woodford exercised and sold in three tranches (sales near $111.98, ~$725K combined across tranches) under a 10b5-1 plan, retaining 62,995 shares - routine rather than alarming
Risk Flags (10)
- American Express/Insider Selling↓ [HIGH RISK]▼
Cluster of sales by Chief Legal Officer Seeger (~$22.9M) and Group President Marrs (~$10.3M) at ~$327-328, close to a level where Amex has been trading, while Joabar, Herena and Grosfield received fresh option grants - a mixed pattern that merits monitoring
- JPMorgan Chase/Capital and Efficiency↓ [HIGH RISK]▼
CET1 ratio fell to 14.0% from 14.8% a year earlier, noninterest expense rose 12%, professional services +23% and marketing +30%, and the overhead ratio reached 54%
- JPMorgan Chase/Securities Losses↓ [HIGH RISK]▼
Investment securities losses of $658M in Q3 2026 versus a $105M gain in Q3 2025, a swing of roughly $763M that compresses reported earnings quality
- Amgen/Biosimilar Erosion↓ [HIGH RISK]▼
Prolia volume fell 23% and total revenue fell -45%, XGEVA fell -47%, Otezla -18%, and TAVNEOS -2% on 9% lower volume and an 8% unfavorable sales-deduction change; Amgen states it continues to engage with the FDA on TAVNEOS
- Amgen/Cash Generation and Buybacks↓ [MEDIUM RISK]▼
Free cash flow fell to $3.7B from $4.2B and no shares were repurchased in the quarter, suggesting capital returns may be deprioritised
- UnitedHealth Group/Mix Shift↓ [MEDIUM RISK]▼
Q3 premiums fell about 2.1% YoY while products revenue rose 7.6% and services rose 5.1%, and total revenue declined 0.4% - top-line growth is weakening even as margins expand
- UnitedHealth Group/Balance Sheet↓ [MEDIUM RISK]▼
Accumulated other comprehensive loss widened to $(3,934)M from $(2,061)M at year-end 2025, driven by unrealised investment losses that will weigh on book value
- Apple/Tax and R&D Intensity↓ [MEDIUM RISK]▼
Effective tax rate rose to 17.0% from 15.6% (provision +31% to $27,062M), and R&D surged 32% to 10% of net sales, pressuring the incremental margin conversion of revenue growth
- Visa/Concentrated Executive Sales↓ [MEDIUM RISK]▼
Two of the top-level executives (President Technology and CEO) sold in the same filing window, with the largest single sale at ~$14.6M, creating an optics issue even though both are partly 10b5-1
- Procter & Gamble/Cluster Selling↓ [MEDIUM RISK]▼
Four insiders including the CEO of Fabric Home & Habitat Care sold within the same window at ~$163-165, with the largest single position sale at $6.31M - a broad-based pattern rather than an isolated event
Opportunities (8)
- Boeing/Director Conviction↓ (OPPORTUNITY)◆
Two directors bought ~$1.5M combined at ~$171-173, an insider signal that is unusual in a stock that has been a laggard in the group; a re-rating thesis rests on the insider buying
- Apple/Services Compounding↓ (OPPORTUNITY)◆
Services net sales of $123.3B (+13%) and Services gross margin rising to $93.9B from $82.3B give a high-margin annuity to a company that grew net sales 15%; the Greater China rebound (+28%) is a re-acceleration catalyst
- UnitedHealth Group/Earnings Inflection↓ (OPPORTUNITY)◆
Operating earnings +52.1% on flat revenue, nine-month EPS of $17.50 (+32.5%) and operating cash flow +34.9% indicate a cost-led margin recovery; medical costs fell 2.6% for nine months, supporting the margin-recovery thesis
- Amgen/New Launch Momentum↓ (OPPORTUNITY)◆
UPLIZNA +191% and IMDELLTRA +128% plus Repatha +37% and EVENITY +39% offset the erosion in Prolia/XGEVA, and Nplate ex-government orders grew 11% (vs 3% reported) - the growth portfolio is becoming large enough to absorb biosimilar losses
- JPMorgan Chase/Earnings Momentum↓ (OPPORTUNITY)◆
Nine-month net income up 20% to $52,954M and diluted EPS up 10% in Q3 with lower net charge-offs and nonperforming assets point to a healthy credit cycle despite higher costs
- Caterpillar/Director Signal↓ (OPPORTUNITY)◆
Fish's ~$620K purchase at $620.39 is the only insider buy in the Caterpillar filing set and provides a clean, low-noise confidence marker for a cyclical industrial
- Walmart/Pre-planned Liquidity↓ (OPPORTUNITY)◆
The Kumar and Bartlett sales are explicitly 10b5-1 with Kumar retaining 1.63M shares; the sale is a routine liquidity event and does not signal a change in conviction, giving an opportunity to accumulate on any weakness in the price
- Procter & Gamble/Euro Financing↓ (OPPORTUNITY)◆
Closing of €3.25B across maturities 2030-2046 at 3.750%-4.625% under an existing S-3 shelf locks in long-dated funding while the company continues to sell insider-held stock at ~$163-165, a combination that favours the debt side of the capital structure
Sector Themes (6)
- Insider Liquidity Cycle in Large-Cap Financials and Staples◆
Of the 26 filings, roughly 17 are Form 4 insider transactions, with sales at American Express (3 sellers), Visa (2), Procter & Gamble (4) and Walmart (2) and only 3 open-market director purchases (Boeing x2, Caterpillar x1); the ratio of sales to purchases indicates routine post-vesting liquidity more than a coordinated bearish call [BULLISH/NEUTRAL]
- Option Grants Continuing Across Financials (NEUTRAL)◆
American Express awarded new stock options to at least six executives (Squeri 74,850; Joabar, Herena, Grosfield, Seeger and Pickett at 17,465-22,455 each) in the same window that its executives sold, illustrating standard annual grant cycles that dilute holders but reinforce retention
- Biosimilar and Pricing Pressure in Pharma (BEARISH)◆
Amgen's Prolia (-45%) and XGEVA (-47%) declines, Otezla (-18%) and the TAVNEOS sales-deduction headwind reflect a broader pattern of erosion in legacy biologics; Merck's phantom-stock grant at $149.52 offers no offset data, so the sector signal rests on Amgen alone
- Margin Expansion Without Revenue Growth (MIXED)◆
UnitedHealth (earnings from operations +52.1% on revenue -0.4%), JPMorgan (net income +6% on revenue +8% but expenses +12%) and Apple (net income +18% on sales +15%) show profit growth outpacing top-line in the cost-efficiency part of the group, but JPMorgan's expense trajectory cuts against the pattern
- Capital Return Discipline Under Scrutiny (BEARISH)◆
Amgen repurchased no shares in Q3 with FCF down to $3.7B, while Apple and JPMorgan maintained earnings momentum; the contrast suggests a divergence between cash-generative firms that are still returning capital and those under balance-sheet or investment pressure
- Accumulated OCI and Unrealised Investment Losses (BEARISH)◆
UnitedHealth's AOCI widened to $(3,934)M from $(2,061)M and JPMorgan booked $658M of investment securities losses in Q3, both reflecting unrealised and realised losses on fixed income portfolios that are weighing on reported equity and earnings
Watch List (7)
- 👁
Track whether further director purchases follow the Mollenkopf and Buckley buys; no scheduled event date was provided in the filings
- Amgen/TAVNEOS FDA Engagement↓ (WATCH)👁
Amgen states it continues to engage with the FDA on TAVNEOS; any regulatory update could move guidance given the -2% revenue print and sales-deduction headwind
-
Next quarterly release should show whether noninterest expense growth (+12%) and the CET1 decline (14.0% vs 14.8%) stabilise; the $658M securities loss reversal is also a key line item
- Apple/Greater China Durability↓ (WATCH)👁
The +28% Greater China rebound after a -4% prior year is the key demand-side question for FY2027 guidance and the rising tax rate (17.0%) should be tracked in the next filing
-
Premiums down ~2.1% YoY with mix shift to products and services; watch the Q4 release for whether medical cost improvement holds and whether the 52.1% operating earnings growth is sustainable
- Visa and American Express/Officer Sales Cadence (WATCH)👁
Monitor follow-on Form 4 filings from Taneja (232,112 shares retained), McInerney (15,174 retained) and Seeger (9,002 retained) for escalation beyond the current 10b5-1-style pattern
-
Notes closed 3 November at 3.750%-4.625% coupons; track whether the cluster of CEO and senior-officer sales at $163-165 continues into subsequent weeks
Filing Analyses
(26)
03-11-2026
Director Fish James C Jr bought 1,000 Common Stock at $620.39 (~$620K). Fish James C Jr holds 4,714 shares after the transaction.
- · Director Fish James C Jr bought 1,000 Common Stock at $620.39 (~$620K)
03-11-2026
Amgen reported third quarter 2026 total revenues up 8% year-over-year to $10.4 billion, with GAAP EPS up 19% to $7.08 and non-GAAP EPS up 14% to $6.45. Performance was mixed across the portfolio: Repatha (+37%), EVENITY (+39%), UPLIZNA (+191%), and IMDELLTRA (+128%) grew strongly, while Prolia (-45%), XGEVA (-47%), Otezla (-18%), and TAVNEOS (-2%) declined as biosimilar competition and pricing pressure weighed. Free cash flow fell to $3.7 billion from $4.2 billion, and no shares were repurchased in the quarter.
- · Nplate growth excluding U.S. government orders was 11% YoY, versus 3% reported
- · Prolia volume fell 23%, with the remainder of the decline split between net selling price and sales deductions
- · TAVNEOS sales declined 2% on 9% lower volume and 8% unfavorable sales deduction changes; Amgen states it continues to engage with the FDA
- · Enbrel sales were pressured by 14% lower net selling price tied to Medicare Part D price setting under the Inflation Reduction Act effective 2026
- · Total operating expenses fell 5% GAAP, largely due to lower amortization of acquisition-related assets, while non-GAAP operating expenses rose 8%
- · Dividends paid were $1.4B in Q3 2026 and no share repurchases occurred during the quarter
- · Q3 2026 dividend of $2.52 per share was a 6% increase over the prior year period
03-11-2026
UnitedHealth Group's Q3 2026 10-Q shows third-quarter revenue of $112,694 Million, down 0.4% YoY from $113,161 Million, while earnings from operations rose 52.1% to $6,563 Million and diluted EPS increased to $4.56 from $2.59. Nine-month revenue grew 0.6% to $336,447 Million, but nine-month diluted EPS of $17.50 was up 32.5% from $13.21, and medical costs were down 2.6% YoY for the nine months, reflecting margin improvement. Total equity rose to $104,129 Million, though accumulated other comprehensive loss widened to $(3,934) Million from $(2,061) Million at year-end 2025.
- · Q3 2026 premiums fell about 2.1% YoY while products revenue rose about 7.6% and services revenue rose about 5.1%, showing mix shift away from premium revenue
- · Accumulated other comprehensive loss widened to $(3934) Million from $(2061) Million at December 31, 2025, driven by unrealized losses on investments
- · Nine-month operating cash flow rose to $25087 Million from $18589 Million, a 34.9% increase YoY
- · Nine-month share repurchases of $5147 Million and dividends of $6170 Million were both higher than the prior-year period in dividends
- · Total debt declined: long-term debt fell to $68714 Million from $72320 Million at year-end 2025, and nine-month debt repayments were $3650 Million
03-11-2026
Group Pres., GMNS Marrs Anna exercised/converted 44,910 Common Stock at $148.45 (~$6.67M). 6 transactions reported in total. Marrs Anna holds 20,508.938 shares after the transaction.
- · Group Pres., GMNS Marrs Anna exercised/converted 44,910 Common Stock at $148.45 (~$6.67M)
- · Group Pres., GMNS Marrs Anna sold 14,630 Common Stock at $326.63 (~$4.78M)
- · Group Pres., GMNS Marrs Anna sold 16,833 Common Stock at $327.25 (~$5.51M)
- · Group Pres., GMNS Marrs Anna sold 13,447 Common Stock at $327.77 (~$4.41M)
- · Group Pres., GMNS Marrs Anna was awarded 22,455 Employee Stock Option (Right to Buy)
- · Group Pres., GMNS Marrs Anna exercised/converted 44,910 Employee Stock Option (Right to Buy)
03-11-2026
Grp. Pres., Global Comm. Serv. Joabar Raymond was awarded 22,455 Employee Stock Option (Right to Buy).
- · Grp. Pres., Global Comm. Serv. Joabar Raymond was awarded 22,455 Employee Stock Option (Right to Buy)
03-11-2026
Chief Colleague Exp. Officer Herena Monique was awarded 17,465 Employee Stock Option (Right to Buy).
- · Chief Colleague Exp. Officer Herena Monique was awarded 17,465 Employee Stock Option (Right to Buy)
03-11-2026
Group Pres., U.S. Cons. Serv. Grosfield Howard was awarded 17,465 Employee Stock Option (Right to Buy).
- · Group Pres., U.S. Cons. Serv. Grosfield Howard was awarded 17,465 Employee Stock Option (Right to Buy)
03-11-2026
JPMorgan Chase reported Q3 2026 net income of $15,305 Million, up 6% YoY, and diluted EPS of $5.57, up 10% YoY, on total net revenue of $50,172 Million (up 8% YoY). Nine-month net income rose 20% to $52,954 Million. Performance was mixed: noninterest expense grew 12% YoY to $27,295 Million, the overhead ratio rose to 54%, the CET1 ratio declined to 14.0% from 14.8% a year earlier, and net charge-offs and nonperforming assets were lower YoY.
- · Investment securities losses of $658 Million in Q3 2026 versus a $105 Million gain in Q3 2025
- · Professional and outside services expense rose 23% YoY and marketing expense rose 30% YoY in Q3 2026
- · Q3 2026 effective tax rate was 24.0% versus 23.2% in Q3 2025
- · Fixed Income Markets revenue fell 4% in Q3 2026 while Equity Markets rose 49%
- · Tangible book value per share rose 7% YoY to $112.64
- · Average deposits in Consumer & Community Banking flat QoQ and Asset & Wealth Management deposits down 3% QoQ
03-11-2026
Amazon.com Inc. (AMZN) filed a Form 13F-HR for the quarter ended September 30, 2026, disclosing its equity holdings in six securities as of that date, with a reported aggregate portfolio value of approximately $3.77 billion. The largest positions are Rivian Automotive (about $2.37 billion across roughly 158.4 million shares) and X-Energy Inc. (about $933.6 million across roughly 65.8 million shares). The filing discloses positions only, so it contains no period-over-period comparison of holdings.
- · Filing covers the quarter ended September 30, 2026 and was filed November 3, 2026 under SEC file number 028-20693.
- · Rivian and X-Energy together account for roughly 87% of the reported $3.77B portfolio value.
- · Filing discloses all positions as sole investment discretion with no shared or other-manager voting/investment authority.
03-11-2026
Chairman and CEO Squeri Stephen J was awarded 74,850 Employee Stock Option (Right to Buy).
- · Chairman and CEO Squeri Stephen J was awarded 74,850 Employee Stock Option (Right to Buy)
03-11-2026
Chief Legal Officer Seeger Laureen sold 69,860 Common Stock at $328.17 (~$22.9M). 4 transactions reported in total. Seeger Laureen holds 9,002.033 shares after the transaction.
- · Chief Legal Officer Seeger Laureen exercised/converted 69,860 Common Stock at $148.45 (~$10.4M)
- · Chief Legal Officer Seeger Laureen sold 69,860 Common Stock at $328.17 (~$22.9M)
- · Chief Legal Officer Seeger Laureen was awarded 17,465 Employee Stock Option (Right to Buy)
- · Chief Legal Officer Seeger Laureen exercised/converted 69,860 Employee Stock Option (Right to Buy)
03-11-2026
Pres., Enterprise Shared Serv. Pickett Denise was awarded 17,465 Employee Stock Option (Right to Buy).
- · Pres., Enterprise Shared Serv. Pickett Denise was awarded 17,465 Employee Stock Option (Right to Buy)
03-11-2026
Executive Vice President Bartlett Daniel J sold 3,346 Common at $124.51 (~$417K). Bartlett Daniel J holds 615,012.533 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Executive Vice President Bartlett Daniel J sold 3,346 Common at $124.51 (~$417K)
03-11-2026
Chief Technology Officer Kumar Suresh sold 166,342 Common at $123.21 (~$20.5M). Kumar Suresh holds 1,632,223.13 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Technology Officer Kumar Suresh sold 166,342 Common at $123.21 (~$20.5M)
03-11-2026
On November 3, 2026, Procter & Gamble closed an underwritten public offering of four euro-denominated notes totaling €3,250,000,000 in aggregate principal, with maturities from 2030 to 2046 and coupons from 3.750% to 4.625%. The filing was made under the company's Form S-3 shelf registration (No. 333-299472), and legal opinions are attached as exhibits. The filing contains no financial results, guidance, or period-over-period performance data, so no growth or decline metrics are reported.
- · Legal opinions were filed as Exhibits 5(a) (Travonte Warren) and 5(b) (Fried, Frank, Harris, Shriver & Jacobson LLP), with related consents as Exhibits 23(a) and 23(b)
- · Notes are listed on the New York Stock Exchange under the existing PG debt trading symbols per the cover page
03-11-2026
Director DIAZ PAUL J was awarded 613.073 Phantom Stock at $149.52 (~$91.7K).
- · Director DIAZ PAUL J was awarded 613.073 Phantom Stock at $149.52 (~$91.7K)
03-11-2026
PRESIDENT, TECHNOLOGY Taneja Rajat sold 34,418 Class A Common Stock at $425.43 (~$14.6M). Taneja Rajat holds 232,112 shares after the transaction.
- · PRESIDENT, TECHNOLOGY Taneja Rajat exercised/converted 34,418 Class A Common Stock at $109.82 (~$3.78M)
- · PRESIDENT, TECHNOLOGY Taneja Rajat sold 34,418 Class A Common Stock at $425.43 (~$14.6M)
- · PRESIDENT, TECHNOLOGY Taneja Rajat exercised/converted 34,418 Employee Stock Option (Right to Buy)
03-11-2026
Chief Executive Officer MCINERNEY RYAN sold 5,875 Class A Common Stock at $416.22 (~$2.45M). MCINERNEY RYAN holds 15,174 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chief Executive Officer MCINERNEY RYAN exercised/converted 5,875 Class A Common Stock at $134.76 (~$792K)
- · Chief Executive Officer MCINERNEY RYAN sold 5,875 Class A Common Stock at $416.22 (~$2.45M)
- · Chief Executive Officer MCINERNEY RYAN exercised/converted 5,875 Employee Stock Option (Right to Buy)
03-11-2026
EVP, Control, Fin Plan & Tax WOODFORD BRENT sold 3,618 Disney Common Stock at $111.98 (~$405K). 6 transactions reported in total. WOODFORD BRENT holds 62,995 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · EVP, Control, Fin Plan & Tax WOODFORD BRENT exercised/converted 2,856 Disney Common Stock at $111.58 (~$319K)
- · EVP, Control, Fin Plan & Tax WOODFORD BRENT sold 2,856 Disney Common Stock at $111.98 (~$320K)
- · EVP, Control, Fin Plan & Tax WOODFORD BRENT exercised/converted 3,618 Disney Common Stock at $105.21 (~$381K)
- · EVP, Control, Fin Plan & Tax WOODFORD BRENT sold 3,618 Disney Common Stock at $111.98 (~$405K)
- · EVP, Control, Fin Plan & Tax WOODFORD BRENT exercised/converted 2,856 Stock Option (Right-to-Buy)
- · EVP, Control, Fin Plan & Tax WOODFORD BRENT exercised/converted 3,618 Stock Option (Right-to-Buy)
03-11-2026
Director MOLLENKOPF STEVEN M bought 2,950 Common Stock at $173.03 (~$510K). MOLLENKOPF STEVEN M holds 6,717 shares after the transaction.
- · Director MOLLENKOPF STEVEN M bought 2,950 Common Stock at $173.03 (~$510K)
03-11-2026
Director Buckley Mortimer J bought 5,820 Common Stock at $171.55 (~$998K). Buckley Mortimer J holds 10,250 shares after the transaction.
- · Director Buckley Mortimer J bought 5,820 Common Stock at $171.55 (~$998K)
03-11-2026
Apple reported full-year fiscal 2026 net sales of $478,834 million, up 15% YoY from $416,161 million, with net income of $132,175 million (up 18%) and diluted EPS of $8.98 (up 20%). Growth was led by iPhone (+21%) and Services (+13%), but Greater China (+28%) rebounded after a 4% decline in the prior year, while iPad and Wearables, Home and Accessories were flat, and R&D spending surged 32% to 10% of net sales.
- · Income tax provision rose 31% to $27,062 million and the effective tax rate increased to 17.0% from 15.6%, compressing the tax benefit relative to pre-tax income growth.
- · Products gross margin rose to $139,659 million from $112,887 million, while Services gross margin rose to $93,943 million from $82,314 million.
- · Services net sales grew 13% to $123,301 million, while Americas (+11%) and Europe (+15%) also grew.
- · Other income/(expense), net swung to $1,174 million from $(321) million in FY2025.
- · Interest rate sensitivity: a 100 basis point rise would reduce investment portfolio fair value by $2,608 million and increase annual interest expense on term debt by $95 million, versus $2,416 million and $129 million respectively in FY2025.
03-11-2026
Chf Rsch, Dev & Innov Officer Aguilar Moses Victor Javier sold 18,812 Common Stock at $164.43 (~$3.09M). Aguilar Moses Victor Javier holds 55,243.0935 shares after the transaction.
- · Chf Rsch, Dev & Innov Officer Aguilar Moses Victor Javier exercised/converted 18,812 Common Stock at $78.52 (~$1.48M)
- · Chf Rsch, Dev & Innov Officer Aguilar Moses Victor Javier sold 18,812 Common Stock at $164.43 (~$3.09M)
- · Chf Rsch, Dev & Innov Officer Aguilar Moses Victor Javier exercised/converted 18,812 Stock Option (Right to Buy)
03-11-2026
CEO-Fabric Home & Habitat Care Raman Sundar G. sold 38,253 Common Stock at $165.00 (~$6.31M). Raman Sundar G. holds 47,744.8463 shares after the transaction.
- · CEO-Fabric Home & Habitat Care Raman Sundar G. exercised/converted 38,253 Common Stock at $98.55 (~$3.77M)
- · CEO-Fabric Home & Habitat Care Raman Sundar G. sold 38,253 Common Stock at $165.00 (~$6.31M)
- · CEO-Fabric Home & Habitat Care Raman Sundar G. exercised/converted 38,253 Stock Option (Right to Buy)
03-11-2026
CEO- Health Care Gama Paul sold 2,894 Common Stock at $165.00 (~$478K). Gama Paul holds 43,898.8803 shares after the transaction.
- · CEO- Health Care Gama Paul sold 2,894 Common Stock at $165.00 (~$478K)
03-11-2026
SVP - Chief Accounting Officer Janzaruk Matthew W. sold 9,479 Common Stock at $163.00 (~$1.55M). Janzaruk Matthew W. holds 1,271.2791 shares after the transaction.
- · SVP - Chief Accounting Officer Janzaruk Matthew W. exercised/converted 9,479 Common Stock at $98.55 (~$934K)
- · SVP - Chief Accounting Officer Janzaruk Matthew W. sold 9,479 Common Stock at $163.00 (~$1.55M)
- · SVP - Chief Accounting Officer Janzaruk Matthew W. exercised/converted 9,479 Stock Option (Right to Buy)
Get daily alerts with 11 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 26 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Dow Jones 30 Stocks SEC Filings
🇺🇸 More from United States
View all →November 03, 2026
US Pre-Market SEC Filings Roundup — November 03, 2026
US Pre-Market SEC Filings Roundup
November 03, 2026
US SEC Filings Daily Market Digest — November 03, 2026
US SEC Filings Daily Market Digest
November 03, 2026
US Corporate Board Director Changes SEC Filings — November 03, 2026
US Corporate Board Director Changes SEC Filings
November 03, 2026
US IPO Pipeline SEC S-1 Filings — November 03, 2026
US IPO Pipeline SEC S-1 Filings